T. M. Coque, A. Novais, A. Carattoli, L. Poirel, J. Pitout et al., Dissemination of clonally related Escherichia coli strains expressing extended-spectrum beta-lactamase CTX-M-15, Emerg Infect Dis, vol.14, pp.195-200, 2008.

D. M. Livermore, R. Canton, M. Gniadkowski, P. Nordmann, G. M. Rossolini et al., CTX-M: changing the face of ESBLs in Europe, J Antimicrob Chemother, vol.59, pp.165-174, 2007.

N. Gruson, C. Bialek-davenet, S. Bertrand, X. Thomas-jean, F. Bert et al., 10-Fold increase (2006-11) in the rate of healthy subjects with extendedspectrum ?-lactamase-producing Escherichia coli faecal carriage in a Parisian check-up centre, J Antimicrob Chemother, vol.68, pp.562-568, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00802788

M. E. Falagas, A. C. Kastoris, A. M. Kapaskelis, and D. E. Karageorgopoulos, Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review, Lancet Infect Dis, vol.10, pp.43-50, 2010.

E. Wenzler, E. J. Ellis-grosse, and K. A. Rodvold, Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous (ZTI-01) and Oral Fosfomycin in Healthy Volunteers, Antimicrob Agents Chemother, vol.61, pp.775-792, 2017.

K. G. Naber, B. Bergman, M. C. Bishop, T. E. Bjerklund-johansen, H. Botto et al., Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU). 2001. EAU guidelines for the management of urinary and male genital tract infections. Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU), Eur Urol, vol.40, pp.576-588

A. Pourbaix, F. Guérin, V. Lastours, . De, F. Chau et al., Biological cost of fosfomycin resistance in Escherichia coli in a murine model of urinary tract infection, Int J Med Microbiol IJMM, vol.307, pp.452-459, 2017.

M. Båga, M. Göransson, S. Normark, and B. E. Uhlin, Transcriptional activation of a pap pilus virulence operon from uropathogenic Escherichia coli, EMBO J, vol.4, pp.3887-3893, 1985.

A. Marchese, L. Gualco, E. A. Debbia, G. C. Schito, and A. M. Schito, In vitro activity of fosfomycin against gram-negative urinary pathogens and the biological cost of fosfomycin resistance, Int J Antimicrob Agents, vol.22, issue.2, pp.53-59, 2003.

G. Martín-gutiérrez, F. Docobo-pérez, J. Rodriguez-beltrán, J. M. Rodríguez-martínez, J. Aznar et al., Urinary Tract Conditions Affect Fosfomycin Activity against Escherichia coli Strains Harboring Chromosomal Mutations Involved in Fosfomycin Uptake, Antimicrob Agents Chemother, vol.62, pp.1899-1916, 2018.

D. E. Karageorgopoulos, R. Wang, X. Yu, and M. E. Falagas, Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens, J Antimicrob Chemother, vol.67, pp.255-268, 2012.

A. C. Dijkmans, N. Zacarías, J. Burggraaf, J. W. Mouton, E. B. Wilms et al., Fosfomycin: Pharmacological, Clinical and Future Perspectives, Antibiot Basel Switz, vol.6, 2017.

S. S. Patel, J. A. Balfour, and H. M. Bryson, Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a singledose oral treatment for acute uncomplicated lower urinary tract infections, Drugs, vol.53, pp.637-656, 1997.

E. Wenzler, S. C. Bleasdale, M. Sikka, K. L. Bunnell, M. Finnemeyer et al.,

, Phase I Study To Evaluate the Pharmacokinetics, Safety, and Tolerability of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adult Participants, Antibacterial Resistance Leadership Group, vol.62, pp.464-482, 2018.

M. L. Grayson, N. Macesic, J. Trevillyan, A. G. Ellis, P. T. Zeglinski et al., Fosfomycin for Treatment of Prostatitis: New Tricks for Old Dogs, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.61, pp.1141-1143, 2015.

K. Spp, from Urinary Tract Infections and the Influence of pH on Fosfomycin Activities, Antimicrob Agents Chemother, vol.61, pp.2498-2514

R. Mann, D. G. Mediati, I. G. Duggin, E. J. Harry, and A. L. Bottomley, Metabolic Adaptations of Uropathogenic E. coli in the Urinary Tract. Front Cell Infect Microbiol, vol.7, p.241, 2017.

A. I. Nilsson, O. G. Berg, O. Aspevall, G. Kahlmeter, and D. I. Andersson, Biological costs and mechanisms of fosfomycin resistance in Escherichia coli, Antimicrob Agents Chemother, vol.47, pp.2850-2858, 2003.

D. M. Gordon and M. A. Riley, A theoretical and experimental analysis of bacterial growth in the bladder, Mol Microbiol, vol.6, pp.555-562, 1992.

A. J. Lepak, M. Zhao, B. Vanscoy, D. S. Taylor, E. Ellis-grosse et al., In Vivo Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa, Antimicrob Agents Chemother, vol.61, pp.476-493, 2017.

H. L. Mobley, D. M. Green, A. L. Trifillis, D. E. Johnson, G. R. Chippendale et al., Pyelonephritogenic Escherichia coli and killing of cultured human renal proximal tubular epithelial cells: role of hemolysin in some strains, Infect Immun, vol.58, pp.1281-1289, 1990.

F. Labat, O. Pradillon, L. Garry, M. Peuchmaur, B. Fantin et al., Mutator phenotype confers advantage in Escherichia coli chronic urinary tract infection pathogenesis, FEMS Immunol Med Microbiol, vol.44, pp.317-321, 2005.

R. Lepeule, E. Ruppé, P. Le, L. Massias, F. Chau et al., Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum ?-lactamase, Antimicrob Agents Chemother, vol.56, pp.1376-1381, 2012.

O. Clermont, S. Bonacorsi, and E. Bingen, Rapid and simple determination of the Escherichia coli phylogenetic group, Appl Environ Microbiol, vol.66, pp.4555-4558, 2000.

O. Tenaillon, D. Skurnik, B. Picard, and E. Denamur, The population genetics of commensal Escherichia coli, Nat Rev Microbiol, vol.8, pp.207-217, 2010.

I. N. Zykov, Ø. Samuelsen, L. Jakobsen, L. Småbrekke, D. I. Andersson et al., Pharmacokinetics and Pharmacodynamics of Fosfomycin and Its Activity against Extended-Spectrum-?-Lactamase-, Plasmid-Mediated AmpC, 2018.

. Carbapenemase-producing, Escherichia coli in a Murine Urinary Tract Infection Model, Antimicrob Agents Chemother, vol.62, pp.2560-2577